The acute effects of human growth hormone (GH) on the basal levels of glucose and insulin in blood were investigated in 11 healthy men. GH doses of 5, 10, 20, and 40 \g=m\g/kgbody weight were given iv as a constantrate infusion over 30 min, and resulted in peak hormone levels (30 min) of 20.5 \ m=+-\ 1.0, 48.5 \ m=+-\ 2.2, 108.2 \ m=+-\ 4.5, and 229.2 \ m=+-\ 14.6 ng/ml, respectively. There was a small (max 9.8 \ m=+-\2.6 %) but significant decrease in the blood glucose level, observed already at 15 min after the beginning of the GH infusion and persisting up to 90 min. The highest dose of GH induced the most marked changes, but there was otherwise no clear correlation between dose and effect. The basal plasma insulin levels showed a more marked (max 16.0 \ m=+-\ 4.7 %) decrease which was not correlated, in time or in magnitude, with the changes in blood glucose. In some subjects, in whom no significant decrease in blood glucose was observed, plasma insulin still demonstrated a similar fall (max 20.2 \ m=+-\7.6 %). Neither were these changes in plasma insulin correlated to the dose of GH within the range used in this study. The 
inducing decreases in blood glucose and serum free fatty acid levels (Westermeyer Sc Raben 1954; Engel et al. 1958; Zahnd et al. 1960; Daughaday Sc Kipnis 1966; Frohman et al. 1967 ). We demonstrated recently that, shortly after an iv infusion of pharmacological amounts of human GH, the glucose tolerance and the insulin response to glucose were lowered in normal man (Cerasi et al. 1972 ). These contradictory results and conclusions raise the question if GH has distinct, independent effects on the blood glucose and plasma insulin levels. The present investigation was undertaken in order to analyse the early action of physiologic to pharmacological doses of GH on the fasting blood glucose and plasma insulin levels in healthy subjects.
MATERIALS AND METHODS
The studies were performed on 11 healthy, non-obese male volunteers, aged [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] years. All had a normal iv glucose tolerance (Ikkos Se Luft 1957) and displayed nor¬ mal insulin response to glucose infusion (Cerasi 8c Luft 1967 (Cerasi et al. 1966 ) with double-antibody radioimmunoassay.
The samples of each test were always analysed in the same assay. For the fasting plasma insulin level, the assay has a within-assay variation of se = 1.8% of the mean (x = 20.9 /¿U/ml, se = 0.38, = 25), and a day-to-day variation of se = 1.9% of the mean (x = 19.0 /¿U/ml, se = 0.37, = 35). For blood glucose, the se is 1.5% of the mean within the same determination. Conventional, statistical methods were employed, the i-test for paired differences being used when applicable (Snedecor 1956 Fig. 1 , the disappearance rate of the hormone (30^9 0 min) was similar at all dose-levels, averaging the half-life of 19.5 ± 0.8 min.
As seen in Table 1 , a small but significant fall in the blood glucose level was induced by GH administration. In the saline controls (six experiments) only a transient fall occurred at 15 min, probably reflecting a dilution effect which is corrected later on. In these same subjects, GH (5 and 10 pg per kg) induced a blood glucose fall of longer duration than saline alone, the maximum fall occurring after 45-60 min (-4.2 ± 1.5 and -3.6 ± 1.3 mg/100 ml respec¬ tively, < 0.05). In the whole group of subjects all GH doses, except the 10 pg/kg one, lowered the blood glucose during and after the infusion period, at least up to 60 min (Table 1) . When 10 pg/kg were infused, no significant change in blood glucose was observed. Although no clear relation between the dose of GH and the decrease in blood glucose was apparent, the most marked effects were obtained with the highest rate of infusion, the maximum decrease being 9.8 ± 2.6% of the basal level. Tables 1 and 2 shows that the changes from the basal levels were percentually greater for insulin than for glucose (maximum 16.0 ± 4.7 % of basal). In five of the subjects (included in Tables 1 and 2 ), the GH infusion of 20 /¿g/kg did not induce decrease of the blood glucose level (Table 3 ). In the same experiments, however, the plasma insulin concentration was signi¬ ficantly reduced, the magnitude of the change being similar to that observed in the total group of subjects.
DISCUSSION
The modifications in the basal glucose and plasma insulin levels described in this report were obtained not only by pharmacological amounts of GH (20 and 40 ¿¿g/kg), but also by doses that induced plasma GH peaks that may be observed spontaneously under physiologic conditions, such as exercise or sleep (Hunter et al. 1965; Honda et al. 1969 ). Therefore, the earlier demonstration of the blood glucose lowering effect of GH with the use of very high doses (Zahnd el al. 1960) or administration of the hormone to GH-deficient subjects (Frohman et al. 1967 ) is extended by the present investigation to normal physiology in man.
The finding that a significant decrease in blood glucose was observed early during GH administration makes it more likely that this is a direct effect of the hormone rather than the consequence of a secondary event, such as genera¬ tion of somatomedins, which is known to necessitate much longer time intervals (Hall 1971) . It has to be emphasized that, whatever the mechanism responsible for it, the insulin-like action of GH is very modest and inconsistent (unless supra-pharmacological doses are used), and its eventual significance in the complex regulation of blood glucose homoeostasis difficult to define.
A finding which is more in keeping with the concept of GH as a diabetogenic and/or stress hormone is the suppression noted in the basal insulin levels. It may be questioned if this decrease in insulin is the simple consequence of the fall in blood glucose concentration. However, the lack of correlation as to the timing and magnitude of the changes between these two parameters, and the demonstration in some subjects that plasma insulin may fall even (1969) showed that GH instead diminishes the destruction of the hormone. Therefore, the results presented here, together with our earlier demonstration that glucose-stimulated insulin response is suppressed by GH (Cerasi et al. 1972) , probably reflect true inhibition of the pancreatic beta-cell. In this sense, GH shows some analogy to catecholamines (Cerasi et al. 1971) , albeit with much less effectiveness.
Chronic administration of GH results in elevation of both the glucose and insulin levels in blood (Luft 8c 
